Spain provides WHO, MPP with first transparent, non-exclusive license for COVID-19 technology

On November 23, 2021, the Spanish National Research Council (CSIC) announced an innovative licensing agreement to provide the World Health Organization (WHO) and the Medicines Patent Pool (MPP) with COVID-19 serological antibody technologies. This move represents the first transparent, global, non-exclusive license for a COVID-19 health tool, and the first test license signed by MPP which is included in the WHO’s COVID-19 Technology Access Pool (C-TAP).

The aim of this license is to facilitate the rapid manufacture and commercialization of CSIC’s COVID-19 serological tests worldwide. CSIC will not receive any patent compensation when the tests are addressed to low- and middle-income countries.

The Spanish Minister of Science and Innovation, Diana Morant, underlined CSIC as the first public body worldwide to reach a licensing agreement with MPP and C-TAP in a public initiative-launch event held in Madrid, Spain. Morant made the case for increasing the Spanish government's strong commitment to employing science and innovation.   

Press release – CSIC (in Spanish)